Study guide
16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage
Key Takeaways Explain This Topic AI
Carotid endarterectomy is indicated for symptomatic stenosis of 50-99% by NASCET criteria and should be performed within two weeks of the index event.
Nimodipine reduces delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage and is given for 21 days.
A normal CT head does not exclude subarachnoid haemorrhage beyond six hours from onset; lumbar puncture at 12 hours looking for xanthochromia is then required.
Last updated: September 2026
- 4. Secondary Prevention & Post-Stroke Care Acute Ischaemic Stroke (CT Brain Excludes Haemorrhage)
- │
- ├── Immediate Antiplatelet: Aspirin 300 mg daily for 14 days
- │ (If thrombolysed: delay aspirin until 24-hour follow-up CT excludes haemorrhagic transformation)
- │
- ├── Dysphagia Assessment: Formal bedside swallow screen BEFORE any oral intake
- │
├── Long-term Antithrombotic Strategy:
- │ ├── Non-cardioembolic (sinus rhythm): Switch at day 14 to Clopidogrel 75 mg once daily indefinitely
- │ └── Cardioembolic (Atrial Fibrillation): Anticoagulation (DOAC) initiated at 5–14 days post-stroke
- │
- ├── Lipid Lowering: High-intensity Atorvastatin 80 mg daily (delayed until >48h or upon discharge)
- │
- └── Carotid Imaging: Carotid Doppler ultrasound for anterior circulation stroke/TIA
Antiplatelet Regimen: Aspirin 300 mg daily orally, enterally, or rectally for 14 days . In thrombolysed patients, aspirin is withheld for 24 hours until a follow-up CT scan confirms absence of significant haemorrhagic transformation. Long-term secondary prevention: Clopidogrel 75 mg monotherapy indefinitely (first-line under NICE guidelines). If clopidogrel is contraindicated or not tolerated, use aspirin 75 mg daily combined with modified-release dipyridamole 200 mg twice daily (or aspirin 75 mg monotherapy).
Lipid Management: Initiate high-intensity statin therapy with Atorvastatin 80 mg once daily irrespective of baseline cholesterol level (aim for ≥ 50 % \ge 50\% ≥ 50% reduction in LDL-cholesterol or LDL < 1.4 mmol/L < 1.4\text{ mmol/L} < 1.4 mmol/L ). Statin therapy is typically started once acute dysphagia is managed and the patient is medically stabilized (within 48 hours to discharge).
Anticoagulation in Atrial Fibrillation: Anticoagulation with a Direct Oral Anticoagulant (DOAC: apixaban, edoxaban, rivaroxaban, or dabigatran) is the gold standard for non-valvular AF. Crucial MRCP Timing Rule: Do NOT start full anticoagulation immediately in acute ischaemic stroke due to excessive risk of haemorrhagic transformation. In practice, aspirin 300 mg is used initially, and oral anticoagulation is introduced according to infarct size:
TIA: Start DOAC immediately or at day 1.
Mild stroke (NIHSS < 8 < 8 < 8 , small infarct): Start DOAC at day 3–5 .
Moderate stroke (NIHSS 8–15): Start DOAC at day 7 .
Severe stroke (NIHSS > 15 > 15 > 15 , large cortical infarct): Delay DOAC until day 14 , often repeating CT brain before initiation to exclude haemorrhagic transformation.
5. Transient Ischaemic Attack (TIA) & Carotid Endarterectomy
Definition: A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia, without acute tissue infarction on neuroimaging.
Emergency Management Pathway:
Immediate Antiplatelet: Administer Aspirin 300 mg stat immediately unless contraindicated, continuing 300 mg daily until specialist neurovascular assessment.
Urgent Neurovascular Clinic: High-risk TIA presentations must be assessed by a specialist stroke team within 24 hours of symptom onset.
Urgent Carotid Duplex Ultrasound: Mandated for all patients with anterior circulation TIA or non-disabling ischaemic stroke who are potential candidates for carotid intervention.
Carotid Endarterectomy (CEA) Indications (NASCET Criteria):
Symptomatic stenosis 70–99%: Strongest benefit; absolute risk reduction of stroke exceeds 16 % 16\% 16% . CEA should be performed urgently within 7 days of symptom onset.
Symptomatic stenosis 50–69%: Moderate benefit; consider CEA, especially in male patients, elderly patients, or those with hemispheric (rather than retinal) symptoms.
Symptomatic stenosis < 50 % < 50\% < 50% : No surgical benefit; manage with intensive medical therapy.
Complete occlusion (100% stenosis): Surgical intervention is contraindicated; manage medically.
DVLA Driving Regulations (UK Law):
Group 1 (Car and Motorcycle): Must stop driving for at least 1 month following a stroke or TIA. They may resume driving after 1 month without notifying the DVLA if clinical recovery is satisfactory and no residual functional neurological deficits impair vehicle control. If significant neurological deficit persists at 1 month, they must notify the DVLA.
Group 2 (Bus and Lorry / HGV): Must stop driving immediately, notify the DVLA, and cannot drive for a minimum of 1 year .
- 6. Intracerebral Haemorrhage & Subarachnoid Haemorrhage
- Spontaneous Intracerebral Haemorrhage (ICH)
Emergency Management: Non-contrast CT confirms hyperdense intraparenchymal haematoma.
Blood Pressure Lowering: In patients presenting within 6 hours of onset with systolic BP 150–220 mmHg, initiate rapid intensive BP reduction within 1 hour targeting systolic BP 130–140 mmHg (using IV labetalol or nicardipine). Avoid reducing systolic BP below 130 mmHg.
Anticoagulant Reversal: Administer immediate reversal agents:
For Warfarin: Four-Factor Prothrombin Complex Concentrate (4F-PCC, 25–50 IU/kg) plus Intravenous Vitamin K 10 mg .
For Dabigatran: Idarucizumab 5 g IV .
For Factor Xa Inhibitors (Apixaban, Rivaroxaban): Andexanet alfa or 4F-PCC (50 IU/kg).
Neurosurgical Consultation: Indicated for infratentorial (cerebellar) haematomas > 3 cm > 3\text{ cm} > 3 cm with brainstem compression or hydrocephalus (mandates urgent surgical evacuation), or supratentorial lobar haematomas with impending herniation.
Aneurysmal Subarachnoid Haemorrhage (SAH)
Presentation: Rupture of intracranial saccular (berry) aneurysm (most commonly anterior communicating artery ~30%, posterior communicating artery ~25%, or MCA bifurcation ~20%). Sudden, catastrophic "thunderclap" headache ("struck by a bat"), peaking within seconds, accompanied by neck stiffness, vomiting, photophobia, and transient loss of consciousness. Oculomotor (CN III) nerve palsy with pupil dilatation strongly points to a posterior communicating artery aneurysm.
Diagnostic Protocol:
Immediate Non-contrast CT Head: Sensitivity exceeds 99 % 99\% 99% within 6 hours of onset. Demonstrates hyperdense blood in the basal cisterns, sylvian fissures, and interhemispheric fissure.
Lumbar Puncture (LP): Mandated if CT head is negative or equivocal, or performed > 6 hours > 6\text{ hours} > 6 hours post-onset. Critical Timing Rule: LP must be performed at least 12 hours after symptom onset to allow enzymatic breakdown of lysed erythrocytes into bilirubin. CSF Spectrophotometry showing xanthochromia (bilirubin absorbance peak at 476 nm) confirms subarachnoid haemorrhage and differentiates it from a traumatic tap (which clears across tubes and shows only oxyhaemoglobin).
Management:
Oral Nimodipine: 60 mg 60\text{ mg} 60 mg every 4 hours for 21 days ; acts as a neuroprotective dihydropyridine calcium channel blocker that prevents delayed cerebral ischaemia (vasospasm) and improves neurological survival.
Aneurysm Securing: Early intervention within 24–48 hours to prevent catastrophic rebleeding. Endovascular coiling is the preferred first-line modality (ISAT trial showed superior disability-free survival compared to open surgical clipping).